(S (PP (IN In) (NP (DT this) (NN paper))) (, ,) (NP (PRP we)) (VP (VBP seek) (NP (NP (DT a) (JJ clinically-relevant) (NN latent) (NN code)) (PP (IN for) (S (VP (VBG representing) (NP (NP (DT the) (NN spectrum)) (PP (IN of) (NP (JJ macular) (NN disease))))))))) (. .))
(S (PP (NNS Towards) (NP (DT this) (NN end))) (, ,) (NP (PRP we)) (VP (VBP construct) (NP (NP (JJ retina-VAE)) (, ,) (NP (NP (DT a) (JJ variational) (JJ autoencoder-based) (NN model)) (SBAR (WHNP (WDT that)) (S (VP (VBZ accepts) (NP (NP (DT a) (NN patient) (NN profile) (NN vector)) (PRN (-LRB- -LRB-) (NP (NN pVec)) (-RRB- -RRB-))) (PP (IN as) (NP (NN input))))))))) (. .))
(S (NP (DT The) (JJ pVec) (NNS components)) (VP (VBP include) (NP (NP (JJ clinical) (JJ exam) (NNS findings)) (CC and) (NP (JJ demographic) (NN information)))) (. .))
(S (NP (PRP We)) (VP (VBP evaluate) (NP (DT the) (NN model)) (PP (IN on) (NP (NP (DT a) (NN subspectrum)) (PP (IN of) (NP (DT the) (JJ retinal) (NNS maculopathies))) (PRN (, ,) (PP (IN in) (ADJP (JJ particular))) (, ,) (NP (NP (JJ exudative) (JJ age-related) (JJ macular) (NN degeneration)) (, ,) (NP (JJ central) (JJ serous) (NN chorioretinopathy)) (, ,) (CC and) (NP (JJ polypoidal) (NN choroidal) (NN vasculopathy))))))) (. .))
(S (PP (IN For) (NP (DT these) (CD three) (NNS maculopathies))) (, ,) (NP (NP (DT a) (NN database)) (PP (IN of) (NP (NP (CD 3000) (JJ 6-dimensional) (NN pVecs)) (PRN (-LRB- -LRB-) (NP (NP (CD 1000)) (NP (DT each))) (-RRB- -RRB-))))) (VP (VBD was) (VP (ADVP (RB synthetically)) (VBN generated) (PP (VBN based) (PP (IN on) (NP (NP (JJ known) (NN disease) (NNS statistics)) (PP (IN in) (NP (DT the) (NN literature)))))))) (. .))
(S (NP (DT The) (NN database)) (VP (VBD was) (ADVP (RB then)) (VP (VBN used) (S (VP (TO to) (VP (VP (VB train) (NP (DT the) (NNP VAE))) (CC and) (VP (VB generate) (NP (JJ latent) (NN vector) (NNS representations)))))))) (. .))
(S (NP (PRP We)) (VP (VBD found) (S (NP (VBG training) (NN performance)) (VP (TO to) (VP (VB be) (ADJP (RB best)) (PP (IN for) (NP (DT a) (JJ 3-dimensional) (NN latent) (NN vector) (NN architecture))) (PP (VBN compared) (PP (TO to) (NP (ADJP (QP (CD 2) (CC or) (CD 4)) (JJ dimensional)) (NNS latents)))))))) (. .))
(S (ADVP (RB Additionally)) (, ,) (PP (IN for) (NP (DT the) (CD 3D) (JJ latent) (NN architecture))) (, ,) (NP (PRP we)) (VP (VBD discovered) (SBAR (IN that) (S (NP (DT the) (VBG resulting) (JJ latent) (NNS vectors)) (VP (VBD were) (VP (ADVP (RB strongly)) (VBN clustered) (ADVP (RB spontaneously)) (PP (IN into) (NP (NP (CD one)) (PP (IN of) (NP (CD 14) (NNS clusters)))))))))) (. .))
(S (NP (NNS Kmeans)) (VP (VBD was) (ADVP (RB then)) (VP (VBN used) (S (ADVP (RB only)) (VP (TO to) (VP (VB identify) (NP (NP (NNS members)) (PP (IN of) (NP (DT each) (NN cluster)))))) (CC and) (VP (TO to) (VP (VB inspect) (NP (NN cluster) (NNS properties))))))) (. .))
(S (NP (DT These) (NNS clusters)) (VP (VBP suggest) (NP (NP (VBG underlying) (NN disease) (NNS subtypes)) (SBAR (WHNP (WDT which)) (S (VP (MD may) (ADVP (RB potentially)) (VP (VB respond) (ADVP (JJR better) (CC or) (JJR worse)) (PP (TO to) (NP (NP (VB particular) (JJ pharmaceutical) (NNS treatments)) (PP (JJ such) (IN as) (NP (JJ anti-vascular) (JJ endothelial) (NN growth) (NN factor) (NNS variants))))))))))) (. .))
(S (NP (DT The) (JJ retina-VAE) (NN framework)) (VP (MD will) (ADVP (RB potentially)) (VP (VB yield) (NP (NP (JJ new) (JJ fundamental) (NNS insights)) (PP (IN into) (NP (NP (DT the) (NNS mechanisms) (CC and) (NNS manifestations)) (PP (IN of) (NP (NN disease)))))))) (. .))
(S (CC And) (VP (MD will) (ADVP (RB potentially)) (VP (VB facilitate) (NP (NP (DT the) (NN development)) (PP (IN of) (NP (NP (JJ personalized) (NNS pharmaceuticals)) (CC and) (NX (NN gene) (NNS therapies))))))) (. .))
